Abstract
Objective: The aim of our study was to review current rebiopsy practice across our cancer network and to develop evidence-based guidelines to assist clinicians and patients in taking the decision when to proceed to repeat prostate biopsy in a UK healthcare setting. Methods: We conducted case note review of patients who underwent more than one prostate biopsy over a 5-year period (2000–2005) within a single cancer network. Results: Multivariate logistic regression analysis demonstrated that the factors from the first biopsy associated with the diagnosis of cancer at rebiopsy were PINATYP (RR = 4.1, p < 0.05), ASAP (RR= 3.9, p< 0.05), HGPIN (RR= 3.8, p< 0.05), abnormal DRE (RR = 2.2, p< 0.05). Histological evidence of inflammation reduced the risk of cancer on rebiopsy in comparison with benign prostatic tissue. Age below 70 also resulted in a reduced risk. PSA doubling time correlated with a final diagnosis of cancer on Pearson correlation test (coefficient -.011). Only 43 patients (21.5%) had the average PSA measurement frequency within 6 months; however, the average PSA measurement frequency was not predictive of cancer diagnosis (between groups ANOVA, p> 0.05). 61 patients were diagnosed with prostate cancer. 38 patients (62%) received definitive local therapy with 13 patients (21%) receiving no immediate treatment. Conclusions: Our retrospective series has defined predictors of a cancer diagnosis on repeat biopsy in a UK population. The findings of this study will form the basis of our local guidelines for the time-being, but there is scope for a large prospective study utilizing the 10 or 12 core protocol recommended by NICE to ascertain the most appropriate frequency of PSA testing and the indications for repeat biopsy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have